Monkeypox primary prevention: Difference between revisions

Jump to navigation Jump to search
Line 17: Line 17:


In the UK, the UK Health Security Agent, in line with the UK Green Book "Immunization against Infectious Disease" policy, recommend JYNNEOS as pre-exposure therapy to individuals at risk of exposure on the basis of an occupational health assessment<ref name="urlassets.publishing.service.gov.uk">{{cite web |url=https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1080838/Recommendations-for-pre-and-post-exposure-vaccination-during-a-monkeypox-incident-6-june-2022.pdf |title=assets.publishing.service.gov.uk |format= |work= |accessdate=2022-06-16}}</ref>.  
In the UK, the UK Health Security Agent, in line with the UK Green Book "Immunization against Infectious Disease" policy, recommend JYNNEOS as pre-exposure therapy to individuals at risk of exposure on the basis of an occupational health assessment<ref name="urlassets.publishing.service.gov.uk">{{cite web |url=https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1080838/Recommendations-for-pre-and-post-exposure-vaccination-during-a-monkeypox-incident-6-june-2022.pdf |title=assets.publishing.service.gov.uk |format= |work= |accessdate=2022-06-16}}</ref>.  
*Pre-exposure vaccination with 2 doses of JYNNEOS with a minimum interval of 28 days
*Pre-exposure vaccination with 2 doses of JYNNEOS with a minimum interval of 28 days<ref name="urlassets.publishing.service.gov.uk">{{cite web |url=https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1080838/Recommendations-for-pre-and-post-exposure-vaccination-during-a-monkeypox-incident-6-june-2022.pdf |title=assets.publishing.service.gov.uk |format= |work= |accessdate=2022-06-16}}</ref>


==References==
==References==
{{Reflist|2}}
{{Reflist|2}}
[[category:needs english review]]
[[category:needs english review]]

Revision as of 14:16, 18 August 2022

Monkeypox Microchapters

Home

Patient Info

Overview

Historical Perspective

Pathophysiology

Epidemiology & Demographics

Risk Factors

Screening

Causes of Monkeypox

Differentiating Monkeypox from other Diseases

Natural History, Complications & Prognosis

Diagnosis

History & Symptoms

Physical Examination

Lab Tests

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Monkeypox primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Monkeypox primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Monkeypox primary prevention

CDC on Monkeypox primary prevention

Monkeypox primary prevention in the news

Blogs on Monkeypox primary prevention

Directions to Hospitals Treating Monkeypox

Risk calculators and risk factors for Monkeypox primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Bassel Almarie M.D.[2]

Overview

The Advisory Committee on Immunization Practices recommends ACAM2000 or JYNNEOS as pre-exposure prophylaxis to individuals at risk of exposure to monkeypox on basis of an occupational assessment[1].

Pre-exposure Prophylaxis

There is no specific vaccine against monkeypox. Previous evidence showed that smallpox vaccine, which was administered to eradicate smallpox, provides cross-protection that is at least 85% effective in preventing monkeypox[2].

The Advisory Committee on Immunization Practices (ACIP) recommends ACAM2000 or JYNNEOS as pre-exposure prophylaxis to individuals at risk of exposure to monkeypox on basis of an occupational assessment[1].

  • ACAM2000 is an FDA approved active immunization against smallpox disease for persons determined to be at high risk for smallpox infection[3].
  • JYNNEOS (MVA-BN), also known as Imvamune or Imvanex, is an FDA approved vaccine to prevent monkeypox and smallpox in adults 18 years of age and older determined to be at high risk for smallpox or monkeypox infection[4].

In the UK, the UK Health Security Agent, in line with the UK Green Book "Immunization against Infectious Disease" policy, recommend JYNNEOS as pre-exposure therapy to individuals at risk of exposure on the basis of an occupational health assessment[5].

  • Pre-exposure vaccination with 2 doses of JYNNEOS with a minimum interval of 28 days[5]

References

  1. 1.0 1.1 Rao AK, Petersen BW, Whitehill F, Razeq JH, Isaacs SN, Merchlinsky MJ; et al. (2022). "Use of JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) for Preexposure Vaccination of Persons at Risk for Occupational Exposure to Orthopoxviruses: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022". MMWR Morb Mortal Wkly Rep. 71 (22): 734–742. doi:10.15585/mmwr.mm7122e1. PMID 35653347 Check |pmid= value (help).
  2. Fine PE, Jezek Z, Grab B, Dixon H (September 1988). "The transmission potential of monkeypox virus in human populations". International Journal of Epidemiology. 17 (3): 643–50. doi:10.1093/ije/17.3.643. PMID 2850277. |access-date= requires |url= (help)
  3. "ACAM2000 | FDA". Retrieved 2022-06-16.
  4. "JYNNEOS | FDA". Retrieved 2022-06-16.
  5. 5.0 5.1 "assets.publishing.service.gov.uk" (PDF). Retrieved 2022-06-16.